Catalys Pacific β Full Portfolio
11 tracked investments Β· listed companies and verified rows first
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)Alex Gold(Chief Medical Officer)Adam Levy(Executive Officer)Alexander Asam(Director)
BoardOlivier Litzka(Director)in
Board seatTakeshi TakahashiBrian Taylor SlingsbyΒ· per SEC Form D Β· $118M raise Β· filed Jun 2022
Co-investorsAndera PartnersSamsara BioCapitalSR One Capital ManagementYsios CapitalBoulder VenturesRA Capital
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechHealthtechLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
Co-investorsAvalon BioVenturesMPM BioImpact
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsNovo HoldingsAN Venture PartnersFrazier Life SciencesLightstone VenturesLongwood Fund
Hepalys Pharma is a late-stage biopharmaceutical company developing innovative therapeutics for liver disease in Japanese and Asian patients, focusing on metabolic dysfunction-associated steatohepatitis (MASH) treatment through its lead candidate Lanifibranor.
BiotechMedical DevicesTokyo, JP
Co-investorsNippon Venture Capital
BiotechSan Diego, US
Eckard Weber, M.D.(Director)Michael Sanders(Executive Officer)Nicole Vitullo(Director)Dennis Podlesak(Executive Officer, Director)Rick Orr(Director)Lynne Rollins(Executive Officer)
Board seatTakeshi TakahashiBrian Taylor SlingsbyΒ· per SEC Form D Β· $25M raise Β· filed Apr 2020
Company addressing social issues in neurology (noted as acquired).
BiotechFintech
Co-investorsFrazier Life SciencesLightspeed Venture PartnersRA CapitalSamsara BioCapital
A multi-asset precision oncology company
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)
Co-investorsAbingworthOrbiMedSamsara BioCapitalKB Investment
Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.
BiotechHealthtech
Mr. Basta(CEO)
Co-investorsFrazier Life SciencesNew Enterprise Associates (NEA)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.